BridgeBio Pharma, Inc. Tax Withholding Paid on Stock Awards
BridgeBio Pharma, Inc. (BBIO) reported Tax Withholding Paid on Stock Awards of $8.34 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-10
- BridgeBio Pharma, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $4.27M, a 113.88% increase year-over-year.
- BridgeBio Pharma, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $4.07M, a 129.39% increase year-over-year.
- BridgeBio Pharma, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $7.43M, a 429.20% increase year-over-year.
- BridgeBio Pharma, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $3.02M, a 109.63% increase year-over-year.
- BridgeBio Pharma, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $14.23M, a 89.02% increase from fiscal 2024.
- BridgeBio Pharma, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $7.53M, a 9.39% increase from fiscal 2023.
- BridgeBio Pharma, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $6.88M, a 340.74% increase from fiscal 2022.
- BridgeBio Pharma, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2022 was $1.56M, a 67.11% decline from fiscal 2021.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $8.34M 10-Q · filed 2026-08-10 | $15.77M derived: sum of 3 quarters · filed 2026-08-10 | $18.80M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $4.07M 10-Q · filed 2026-05-07 | $11.50M derived: sum of 2 quarters · filed 2026-05-07 | $14.53M derived: sum of 3 quarters · filed 2026-05-07 | $16.52M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $7.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $10.46M derived: sum of 2 quarters · filed 2026-02-24 | $12.45M derived: sum of 3 quarters · filed 2026-08-10 | $14.23M 10-K · filed 2026-02-24 |
| 2025-09-30 | $3.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $5.02M derived: sum of 2 quarters · filed 2026-08-10 | $6.80M 10-Q · filed 2025-10-29 | $8.20M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $3.77M 10-Q · filed 2026-08-10 | $5.17M derived: sum of 3 quarters · filed 2026-08-10 | $6.62M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $1.78M 10-Q · filed 2026-05-07 | $3.18M derived: sum of 2 quarters · filed 2026-05-07 | $4.62M derived: sum of 3 quarters · filed 2026-05-07 | $6.37M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.85M derived: sum of 2 quarters · filed 2026-02-24 | $4.59M derived: sum of 3 quarters · filed 2026-02-24 | $7.53M 10-K · filed 2026-02-24 |
| 2024-09-30 | $1.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $3.19M derived: sum of 2 quarters · filed 2025-10-29 | $6.12M 10-Q · filed 2025-10-29 | $8.68M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $1.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $4.68M 10-Q · filed 2025-08-05 | $7.23M derived: sum of 3 quarters · filed 2026-02-24 | $9.84M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $2.94M 10-Q · filed 2025-04-29 | $5.49M derived: sum of 2 quarters · filed 2026-02-24 | $8.10M derived: sum of 3 quarters · filed 2026-02-24 | $9.30M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $5.17M derived: sum of 2 quarters · filed 2026-02-24 | $6.37M derived: sum of 3 quarters · filed 2026-02-24 | $6.88M 10-K · filed 2026-02-24 |
| 2023-09-30 | $2.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $3.81M derived: sum of 2 quarters · filed 2024-11-12 | $4.33M 10-Q · filed 2024-11-12 | $4.81M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $1.72M 10-Q · filed 2024-08-01 | $2.20M derived: sum of 3 quarters · filed 2025-02-20 | $2.80M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $512.00K 10-Q · filed 2024-05-02 | $1.00M derived: sum of 2 quarters · filed 2025-02-20 | $1.60M derived: sum of 3 quarters · filed 2025-02-20 | $1.96M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $489.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $1.08M derived: sum of 2 quarters · filed 2025-02-20 | $1.45M derived: sum of 3 quarters · filed 2025-02-20 | $1.56M 10-K · filed 2025-02-20 |
| 2022-09-30 | $596.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $962.00K derived: sum of 2 quarters · filed 2023-11-02 | $1.07M 10-Q · filed 2023-11-02 | $1.78M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $366.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $476.00K 10-Q · filed 2023-08-03 | $1.19M derived: sum of 3 quarters · filed 2024-02-22 | $1.92M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $110.00K 10-Q · filed 2023-05-04 | $821.00K derived: sum of 2 quarters · filed 2024-02-22 | $1.55M derived: sum of 3 quarters · filed 2024-02-22 | $3.83M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $711.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $1.44M derived: sum of 2 quarters · filed 2024-02-22 | $3.73M derived: sum of 3 quarters · filed 2024-02-22 | $4.75M 10-K · filed 2024-02-22 |
| 2021-09-30 | $733.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $3.01M derived: sum of 2 quarters · filed 2022-11-03 | $4.04M 10-Q · filed 2022-11-03 | $4.51M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $2.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $3.30M 10-Q · filed 2022-08-04 | $3.77M derived: sum of 3 quarters · filed 2023-02-23 | |
| 2021-03-31 | $1.02M 10-Q · filed 2022-05-05 | $1.49M derived: sum of 2 quarters · filed 2023-02-23 | ||
| 2020-12-31 | $471.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $714.00K 10-K · filed 2023-02-23 | ||
| 2020-09-30 | $243.00K 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |